2023
Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, Henke P, Sedrakyan A, Mena-Hurtado C. Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC Cardiovascular Interventions 2023, 16: 332-343. PMID: 36792257, PMCID: PMC10359106, DOI: 10.1016/j.jcin.2022.09.022.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyPeripheral vascular interventionsMedical therapyVascular interventionsEnzyme inhibitors/angiotensin receptor blockersVascular Quality Initiative registryAngiotensin receptor blockersLong-term mortalityRisk of amputationRisk of mortalityNational quality registryQuality improvement effortsAmputation outcomesAmputation riskMajor amputationAntiplatelet therapyCause mortalityReceptor blockersMean ageVascular careQuality registryObservational studyMortality riskHigh riskAmputation data
2021
Guideline-Directed Medical Therapy in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Intervention
Jelani QU, Llanos-Chea F, Bogra P, Trejo-Paredes C, Huang J, Provance JB, Turner J, Anantha-Narayanan M, Sheikh AB, Smolderen KG, Mena-Hurtado C. Guideline-Directed Medical Therapy in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Intervention. American Journal Of Nephrology 2021, 52: 845-853. PMID: 34706363, DOI: 10.1159/000519484.Peer-Reviewed Original ResearchConceptsComorbid chronic kidney diseaseGuideline-directed medical therapyPeripheral vascular interventionsCritical limb ischemiaMedian odds ratioMedical therapyPrescription ratesVascular interventionsHigh riskUse of GDMTAdjusted median odds ratioVascular Quality Initiative databaseAngiotensin-converting enzyme inhibitorAngiotensin receptor blockersChronic kidney diseaseLower prescription ratesPoor clinical outcomeCKD groupCKD statusAntiplatelet therapyReceptor blockersLimb ischemiaLimb outcomesClinical outcomesMedical management
2013
Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry
Smolderen KG, Spertus JA, Tang F, Oetgen W, Borden WB, Ting HH, Chan PS. Treatment Differences by Health Insurance Among Outpatients With Coronary Artery Disease Insights From the National Cardiovascular Data Registry. Journal Of The American College Of Cardiology 2013, 61: 1069-1075. PMID: 23375933, PMCID: PMC3641586, DOI: 10.1016/j.jacc.2012.11.058.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAmbulatory CareAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDrug UtilizationFemaleHumansHypolipidemic AgentsInsurance, HealthMaleMedicaidMedically UninsuredMedicareMiddle AgedPlatelet Aggregation InhibitorsRegistriesUnited StatesUnited States Department of Veterans AffairsUnited States Indian Health ServiceConceptsCoronary artery diseaseUninsured patientsEvidence-based treatmentsInsurance statusARB therapyAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersEnzyme inhibitors/angiotensin II receptor blockersAngiotensin II receptor blockersNational Cardiovascular Data RegistryPublic insuranceEvidence-based medicationsLipid-lowering therapyII receptor blockersLeft ventricular dysfunctionHealth insuranceTreatment differencesPoisson regression modelsPINNACLE RegistryPhysician adherenceVentricular dysfunctionReceptor blockersArtery diseaseCardiac RegistryCardiac outpatientsData registry